77 related articles for article (PubMed ID: 38356955)
21. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS; Robinson B; Sherman SI; Krajewska J; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Hernando J; Faoro L; Banerjee K; Oliver JW; Keam B; Capdevila J
Lancet Oncol; 2021 Aug; 22(8):1126-1138. PubMed ID: 34237250
[TBL] [Abstract][Full Text] [Related]
22. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
23. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA; Lawson DH; Wu C; Steuer CE; El-Rayes BF; Khuri FR; Lonial S; Waller EK; Ramalingam SS; Owonikoko TK
Br J Cancer; 2020 Oct; 123(8):1228-1234. PubMed ID: 32704173
[TBL] [Abstract][Full Text] [Related]
25. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
26. Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Sakai R; Nakayama H; Hatori S; Toda S; Masudo K
Oncol Lett; 2019 Jun; 17(6):5292-5300. PubMed ID: 31186746
[TBL] [Abstract][Full Text] [Related]
27. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
Allin DM; Shaikh R; Carter P; Thway K; Sharabiani MTA; Gonzales-de-Castro D; O'Leary B; Garcia-Murillas I; Bhide S; Hubank M; Harrington K; Kim D; Newbold K
Eur J Cancer; 2018 Nov; 103():165-175. PubMed ID: 30253333
[TBL] [Abstract][Full Text] [Related]
29. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.
Romei C; Tacito A; Molinaro E; Piaggi P; Cappagli V; Pieruzzi L; Matrone A; Viola D; Agate L; Torregrossa L; Ugolini C; Basolo F; De Napoli L; Curcio M; Ciampi R; Materazzi G; Vitti P; Elisei R
Oncol Lett; 2018 Jun; 15(6):9174-9182. PubMed ID: 29805648
[TBL] [Abstract][Full Text] [Related]
30. Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer.
Wächter S; Wunderlich A; Roth S; Mintziras I; Maurer E; Hoffmann S; Verburg FA; Fellinger SA; Holzer K; Bartsch DK; Di Fazio P
J Clin Med; 2018 May; 7(5):. PubMed ID: 29762469
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
32. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Faggiano A; Modica R; Severino R; Camera L; Fonti R; Del Prete M; Chiofalo MG; Aria M; Ferolla P; Vitale G; Pezzullo L; Colao A
Endocrine; 2018 Oct; 62(1):46-56. PubMed ID: 29572709
[TBL] [Abstract][Full Text] [Related]
33. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
[No Abstract] [Full Text] [Related]
34. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
35. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; Roozen IC; Bos M; Corver WE; van Wezel T; Smit JW; Morreau H; Guchelaar HJ; Kapiteijn E
J Clin Endocrinol Metab; 2017 Feb; 102(2):698-707. PubMed ID: 27870581
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
37. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.
de Wit D; Schneider TC; Moes DJ; Roozen CF; den Hartigh J; Gelderblom H; Guchelaar HJ; van der Hoeven JJ; Links TP; Kapiteijn E; van Erp NP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):63-71. PubMed ID: 27169792
[TBL] [Abstract][Full Text] [Related]
38. Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.
Manohar PM; Beesley LJ; Taylor JM; Hesseltine E; Haymart MR; Esfandiari NH; Hanauer DA; Worden FP
J Thyroid Disord Ther; 2015 Aug; 4(3):. PubMed ID: 27088062
[TBL] [Abstract][Full Text] [Related]
39. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
40. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
